NanoVibronix, under the leadership of CEO Dr. Doron Besser, is undergoing a strategic rebranding to prioritize its ENvue feeding tube placement system. This decision follows a thorough review of the company’s operations and market opportunities, identifying ENvue as a key growth platform. The FDA-cleared system offers real-time anatomical navigation for enteral tube placements and is seen as a modern solution in a growing market projected to reach $1.8 billion in the U.S. by 2030.
The company, soon to be renamed ENvue Medical, plans to enhance its hospital presence and develop a comprehensive enteral-feeding ecosystem through internal and external initiatives. New opportunities include expanding into pediatric and pre-term infant care and integrating X-ray navigation with electromagnetic mapping. The company is also advancing robotic technologies to improve accuracy in tube placement.
In addition to focusing on ENvue, NanoVibronix is exploring strategic alternatives for its legacy products, such as UroShield, potentially through partnerships or divestitures. The company is energized by the momentum of ENvue and is preparing to announce new board members and leadership team additions following its Annual Meeting on December 4, 2025.
